novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Os muito idosos, os benefícios da ACO e o risco hemorrágico

19 Janeiro 2015

António Pedro Machado
Internista Hospital de Santa Maria, Lisboa

Prevenção secundária nas SCA. Há lugar para anticoagulação oral?

19 Janeiro 2015
0

Coronary artery disease: vulnerable plaques or vulnerable patients

5 Março 2015
0

-->